Soligenix Inc (SNGX)

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases in the United States. The company operates through two segments: Specialized BioTherapeutics and Public Health Solutions. Its Specialized BioTherapeutics pipeline includes SGX301 (HyBryte), a photodynamic therapy that has completed a Phase 3 trial for cutaneous T-cell lymphoma; SGX942, an innate defense regulator program in Phase 3 development for inflammatory conditions, including oral mucositis in head and neck cancer; SGX945, which is in Phase 2a testing for aphthous ulcers in Behçet’s disease; and SGX302, also in Phase 2a development for mild-to-moderate psoriasis. The Public Health Solutions segment includes RiVax, a ricin toxin vaccine candidate that has completed early clinical studies, as well as additional vaccine and anti-infective programs in preclinical development. The company, formerly known as DOR BioPharma, adopted the Soligenix name in 2009 and is headquartered in Princeton, New Jersey.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.